BCR and metastatic neoplasm: Despite these differences, our results suggest that similar to SUVmax, PSMATL may be used to predict PSA levels and subgroups in patients with localised PCa, and similar to above, potentially may be extrapolated to those with locoregional and metastatic disease, as well as in patients with BCR.